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Background: Prostate cancer is a leading cause of cancer among men. Because screening for prostate cancer is a controversial
issue, many experts in the field have defended the use of shared decision making using validated decision aids, which can be
presented in different formats (eg, written, multimedia, Web). Recent studies have concluded that decision aids improve knowledge
and reduce decisional conflict.
Objective: This meta-analysis aimed to investigate the impact of using Web-based decision aids to support men’s prostate
cancer screening decisions in comparison with usual care and other formats of decision aids.
Methods: We searched PubMed, CINAHL, PsycINFO, and Cochrane CENTRAL databases up to November 2016. This search
identified randomized controlled trials, which assessed Web-based decision aids for men making a prostate cancer screening
decision and reported quality of decision-making outcomes. Two reviewers independently screened citations for inclusion criteria,
extracted data, and assessed risk of bias. Using a random-effects model, meta-analyses were conducted pooling results using
mean differences (MD), standardized mean differences (SMD), and relative risks (RR).
Results: Of 2406 unique citations, 7 randomized controlled trials met the inclusion criteria. For risk of bias, selective outcome
reporting and participant/personnel blinding were mostly rated as unclear due to inadequate reporting. Based on seven items, two
studies had high risk of bias for one item. Compared to usual care, Web-based decision aids increased knowledge (SMD 0.46;
95% CI 0.18-0.75), reduced decisional conflict (MD –7.07%; 95% CI –9.44 to –4.71), and reduced the practitioner control role
in the decision-making process (RR 0.50; 95% CI 0.31-0.81). Web-based decision aids compared to printed decision aids yielded
no differences in knowledge, decisional conflict, and participation in decision or screening behaviors. Compared to video decision
aids, Web-based decision aids showed lower average knowledge scores (SMD –0.50; 95% CI –0.88 to –0.12) and a slight decrease
in prostate-specific antigen screening (RR 1.12; 95% CI 1.01-1.25).
Conclusions: According to this analysis, Web-based decision aids performed similarly to alternative formats (ie, printed, video)
for the assessed decision-quality outcomes. The low cost, readiness, availability, and anonymity of the Web can be an advantage
for increasing access to decision aids that support prostate cancer screening decisions among men.
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Introduction
Prostate Cancer and Screening
According to the GLOBOCAN worldwide estimates of cancer
incidence and mortality produced by the International Agency
for Research on Cancer, there were 1,111,700 new cases of
prostate cancer and 307,500 prostate cancer deaths in 2012,
making prostate cancer the second most commonly diagnosed
cancer in men and the fifth leading cause of cancer deaths among
men [1].
Screening for prostate cancer remains a controversial issue,
particularly after data from two major trials were released. The
United States Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial found no benefits from using prostate-specific
antigen (PSA) screening for prostate cancer diagnoses [2]. The
results from the European Randomised Study of Screening for
Prostate Cancer with data truncated at 13 years concluded that
one prostate cancer death would be avoided and 27 excess cases
detected per 781 men invited for screening with PSA [3].
Overdiagnosis was estimated to be as high as 41%. The
proportion of prostate cancer that would never have led to
clinical symptoms resulted in unnecessary biopsy procedures
and treatment with potential side effects, which may include
urinary, sexual (eg, erectile dysfunction), and gastrointestinal
complications [4]. The CAP Randomized Clinical Trial was
recently published and reported no significant difference in
prostate cancer mortality with PSA screening after a median
follow-up of 10 years but an increase in the detection of low-risk
prostate cancer cases [5].
Although often encouraged by media and health care providers,
prostate cancer screening is currently recommended by only a
few organizations. After reviewing the available evidence, the
United States Preventive Services Task Force released a draft
recommendation in 2017, assigning a “C” grade
recommendation to prostate cancer screening in men 55-69
years old, stating that the potential benefits and adverse effects
of PSA-based screening are closely balanced in that age group.
The decision about whether to be screened should be an
individual one based on conversations with the physician about
the benefits and adverse effects of screening in order to help
men make a decision based on personal values and preferences
[6]. Many experts defend a shared decision-making process
involving doctor and patient, using validated decision aids. In
fact, many guidelines issued by medical organizations such as
the European Association of Urology [7], the American Cancer
Society [8], and the American College of Physicians [9] support
a shared decision-making process for prostate cancer screening.
Shared Decision Making and Decision Aids
According to the International Patient Decision Aids Standards
Collaboration (IPDAS), decision aids are evidence-based tools
designed to help people participate in decision making about
health care options with the aim of improving the quality of the
decision. Many study groups have focused on the development
of decision aids to support shared decision making [10,11].
As established in the original IPDAS background document,
two constructs are critical for establishing the effectiveness of
a decision aid: (1) the quality of both the decision-making
process and (2) the actual decision. For the quality of the
decision-making process, five attributes are defined, all of which
are measured by different scales: (1) recognizing that a decision
needs to be made, (2) feeling informed about the options, (3)
understanding what values matter most for the decision, (4)
discussing preferences with their practitioner, and (5) being
involved in decision making. Concerning the decision quality,
two core attributes should be measured: (1) a patient’s
knowledge of the options and outcomes and (2) agreement
between the chosen option and the features that matter most for
the patient [12].
The most recent systematic review and meta-analysis assessing
the impact of decision aids for screening decisions concluded
that decision aids can increase patient knowledge, make people
feel clearer about their values, reduce decisional conflict, and
promote an active patient role in decision making [13]. The
authors state that more studies are needed to deepen
understanding of format issues such as Web-based delivery of
decision aids. In addition, if new studies can be included in the
systematic review, it may be possible to sort out the reasons for
heterogeneity of results (eg, the format of the decision aid).
Another systematic review, focusing on decision aids for
prostate cancer screening, reported similar results [14].
Decision aids may be implemented in different formats,
including written (eg, pamphlet/booklet), multimedia (eg, video,
DVD), or Web-based. Syrowatka et al, in a systematic review
and meta-analysis that assessed computer-based decision aids
for any preference-sensitive medical decision, concluded that
decision aids are associated with a significant improvement in
knowledge and decrease in decisional conflict. However, results
were limited by high levels of heterogeneity [15]. Nevertheless,
the scope of the latter review was broader, including any
preference-sensitive medical decision. Thus, it did not
specifically address prostate cancer screening. In addition, the
authors included all decision aid formats that could be accessed
with a computer (eg, Web-based, videobooklet, CD-ROM).
With the increasing use and ease of access to the internet, the
Web has been proposed as a promising way of delivering
decision aids. Therefore, it is important to assess the impact of
Web-based decision aids in the prostate cancer screening
decision-making process, but the number of studies addressing
this subject to date have been scarce and showed mixed results.
The IPDAS Collaboration identified 12 dimensions to assess
quality of patient decision aids, one of which focused on the
delivery of decision aids on the internet [16]. In fact, several
theories point out the potential benefits of the internet to provide
broad long-term dissemination of information that can be
targeted and tailored to patient needs and preferences. Hence,
IPDAS emphasized that a comprehensive systematic review
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focusing on the internet delivery of decision aids was needed
[17].
To our knowledge, ours is the first systematic review and
meta-analysis to compare Web-based decision aids with usual
care and other formats of decision aids. We sought to investigate
their impact on decision quality for men making a screening
decision regarding prostate cancer.
Methods
Criteria for Considering Studies for This Review
We included randomized controlled trials (RCTs) involving
men who had not been previously diagnosed with prostate cancer
and who were making screening decisions concerning prostate
cancer. We included studies comparing Web-based decision
aids to several parameters: (1) no intervention/usual care or (2)
alternative decision aids formats. For interventions to be
considered Web-based, they had to correspond to any program
accessed over a network connection using HTTP or through a
Web-based app. According to this definition, materials such as
CD-ROMs or DVDs, although computer-based, were not
considered Web-based. Thus, studies with such interventions
were excluded. We included studies in which at least one quality
of decision-making outcome (eg, knowledge, decisional conflict,
and involvement in decision making) was reported. Screening
behavior, either the intention to undergo PSA screening or
undergoing the actual PSA screening, were defined as secondary
outcomes.
Search Methods for Identification of Studies
Electronic Searches
Our search strategy for this review included searching electronic
medical and social science databases: (1) PubMed, (2)
Cumulative Index to Nursing and Allied Health Literature
(CINAHL), (3) PsycINFO, and (4) Cochrane CENTRAL
(Cochrane Central Register of Controlled Trials). Whenever
possible, the search strategies (Multimedia Appendix 1) used a
combination of free text and database-specific subject headings.
The search was conducted in November 2016.
Searching Other Resources
We also searched trial registries (World Health Organization,
National Institutes of Health, ClinicalTrials.gov), reference lists
of included trials, and the Decision Aid Library Inventory.
Data Collection and Analysis
Selection of Studies
Two reviewers screened the titles and abstracts of all retrieved
articles after employing the search strategy. Those included
after screening were accessed in full text. Authors were
contacted to clarify study eligibility. Disagreements were
resolved by consensus among 3 reviewers.
Data Extraction and Management
Data extraction was performed independently by 2 reviewers.
Extracted data included study design and setting, numbers, and
other characteristics of study participants and interventions in
addition to outcomes and other information thought to be
relevant. Whenever different publications reported on the same
trial, the data corresponding to the latest follow-up were
included. For cluster RCTs, we collected effect estimates and
standard errors from analyses that took the clustering into
account. Study authors were contacted when more detailed
information was needed. Disagreements were resolved by
consensus. When available, data resulting from imputation were
used in the analysis in accordance with an intention-to-treat
approach.
Assessment of Risk of Bias in Included Studies
Assessment of risk of bias was performed using the Cochrane
tool for judging risk of bias [18].
Measures of Treatment Effect and Data Synthesis
We used mean differences (MD) for continuous variables that
were measured with the same instrument, standardized mean
differences (SMD) when a similar outcome was assessed with
different instruments, and relative risks (RR) for dichotomous
variables. Continuous variables were standardized to a scale of
0-100. In cases where outcome data (eg, standard deviations)
were missing, we tried to reach one of the study authors by
email to request the complete measures. If we were unsuccessful
in obtaining the data from authors, we derived standard
deviations from standard errors or confidence intervals [18].
We analyzed studies comparing Web-based decision aids to
usual care separately from studies comparing Web-based
decision aids to decision aids presented in a diverse format.
Review Manager 5.3.5 software was used to estimate
meta-analytical-weighted treatment effects across studies [19].
Data analysis was conducted with a random-effects model given
the heterogeneity among studies being pooled.
Sensitivity Analysis
A sensitivity analysis was conducted in order to reassess the
effect measures after excluding trials classified as having high
risk of bias for any of the chosen parameters and after applying
the fixed-effects model. For the knowledge outcome, a
sensitivity analysis was done using MDs as an alternative to
SMDs. Although we opted for SMD to pool knowledge across
studies since different constructs were used to measure this
outcome, the use of MD could also be defensible, as the scale
itself is the same.
Results
Results of the Search and Description of Studies
The electronic database search retrieved 2406 unique citations
(2536 records), and 86 additional citations were identified
through other sources (Figure 1). Of the 32 full-text articles
assessed, 25 were excluded (Figure 1 describes the reasons, and
further details are provided in Multimedia Appendix 2). We
contacted 4 investigators to clarify methodological issues and
to complete the extracted data when necessary.
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Figure 1. Study flow diagram. RCT: randomized controlled trial.
Included Studies
Seven studies met our inclusion criteria and were included in
the meta-analysis. The characteristics of included studies are
presented in Table 1.
The studies were published between 2003 and 2013; five were
based in the United States [20-26], one in Australia [25], and
one in the United Kingdom [26]. A total of 4714 men with ages
ranging from 45-75 years participated in the seven included
studies. Five of the studies recruited men from a primary care
setting [20-22,24,26], one through a radio and newspaper
advertisement [25], and another from an industrial
manufacturing worksite [23]. Six of the studies randomized
individual patients [21,22,24-26], while one used the worksite
as the unit of randomization [23]. For this review, we referred
to control interventions as usual care unless they fulfill the
definition of a patient decision aid. Among the included studies,
five studies compared Web-based decision aid performance to
the usual care [22-24,26], four studies compared Web-based
decision aids to printed decision aids [20,24-26], and two studies
compared Web-based decision aids to video decision aids
[20,25]. In addition to containing information about the options
and outcomes regarding prostate cancer screening, all decision
aids used in the studies provided a values clarification tool,
except for one [25]. All included studies assessed knowledge,
and six measured decisional conflict [21-26]. Others reported
outcomes included anxiety [25,26], satisfaction with decision
[20,24], decision-making role [21,23,25], and intention to
undergo and actually undergoing PSA screening [21-26]. All
studies used a parallel design, except Allen et al, who used a
cluster RCT. Allen et al used a generalized estimating equations
analysis and thus properly accounting for the cluster design and
the possible associated unit-of-analysis errors.
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Table 1. Characteristics of included studies.
OutcomesComparisonParticipantsMethodsStudy
Primary outcome measures: (1)
participant ratings of conve-
Decision aid: Web-based, with infor-
mation, pros and cons of PSA testing,
Men aged ≥50 years consid-
ering PSAb screening in a




nience, effort required, and sat-
isfaction with the intervention,
experiences of other patients, values
clarification exercise
Active comparator: Video, same
content of the Web decision aid
preventive medicine clinic
(USA): 112 (Web)/ 114
(video) (2) knowledge about prostate
cancer screening and treatment,
and (3) choice of undergoing
PSA test
Primary outcome: patient-report-
ed control preferences scale
Decision aid: Web-based information
about prostate cancer, screening,
Men aged 50-70 years con-
sidering PSA screening in a
RCT, comparing Web-
based decision and paper-
Krist 2007 [21]
score. Other: Prostate cancerscreening benefits, and known risks,primary care setting (USA):based decision aids ver-
screening knowledge, timecurrent uncertainties. The website was226 (Web)/ 196 (paper)/ 75
(usual care-control)
sus no intervention (usual
care) spent discussing screening,
topics covered in the discus-
reviewed by a general decision aid
expert and several content experts.
Active comparator: print brochure,
which duplicated the content of the
website
Comparator: usual care
sion, decisional conflict scale
score and whether a PSA test
was ordered
Primary outcome measures: (1)
knowledge; (2) actual option;
Decision aid: information about
prostate cancer screening and treat-
Men aged ≥50 years consid-
ering PSA screening in a
RCT, 4 groups: Web-
based decision aid (1) vs
Frosch 2008 [22]
(3) decisional conflict. Otherment, with physician and patient testi-preventive medicine clinicWeb decision aid +
outcomes: (1) treatment prefer-monials contrasting different prefer-
ences and decisions
Active comparator: chronic disease
trajectory model that prompted pa-
(USA): 155 (1) + 152 (2) +
153 (3) + 151 (4)
chronic disease trajectory
(2) vs chronic disease
trajectory (3) vs usual
care (internet info) (4)
ence if cancer diagnosed and
(2) concern about prostate can-
cer
tients to express utilities for outcomes
associated with a prostate cancer life
course by contrasting screening with
no screening in its impact on quality
of life and longevity
Comparator: links to public websites
on prostate cancer screening main-
tained by the American Cancer Soci-
ety and the Centers for Disease Con-
trol and Prevention
Primary outcomes: (1) decision-
al status, (2) prostate cancer
Decision aid: Web-based (content
based on expert opinion and guide-
lines from IPDASc).
Comparator: no intervention
Men aged ≥45 years consid-
ering PSA screening (USA):
398 (Web)/ 414 (no interven-
tion)
RCT, 2 groups (Web and
control)
Allen 2010 [23]
knowledge, (3) decision self-
efficacy, (4) consistency be-
tween values, and (5) screening
decision. Secondary outcomes:
(1) preference for control in
decision making and (2) deci-
sional conflict
Knowledge, decisional conflict
scale, satisfaction with decision
Decision aid: Web-based
Active comparator: printed decision
aid
Comparator: usual care
Both decision aids share same con-
tent: (1) description of screening tests
Men aged 45-70 years con-
sidering PSA screening in a
primary care setting (USA):
631 (Web)/ 630 (paper)/ 632
(usual care)
RCT, 3 groups (Web, pa-
per, and control)
Taylor 2013 [24]
scale, prostate cancer screening
uptake. Measured at baseline,
and then after 1 and 13 months
and possible results, (2) information
about treatment options, risks and
adverse effects, (3) a review of
prostate cancer risk factors and encour-
agement to discuss screening with a
physician, and (4) a 10-item values
clarification tool; and resources for
more information. Web-based deci-
sion aids also included interactive
features (eg, testimonials, interactive
values clarification tools)
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Decision aid contents: (1) epidemiol-
ogy on prostate cancer, (2) diagnostic
process, (3) treatment options, and (4)
the associated benefits/risks
Men aged ≥45 years consid-
ering PSA screening in
Australia, recruited by radio
and newspaper advertise-
ments: 56 (Web)/ 50 (pam-
phlet)/ 55 (video)




of prostate cancer and PSA.
Other: attitudes towards PSA
testing; behavior (intention to
undergo PSA testing), anxiety,
decisional conflict, and actually
undergoing of PSA test (at 6
months)
Decision aid: Web-based - Prosdex:
information, pros and cons of PSA
testing, other patient experiences,
values clarification exercise
Active comparator: paper version
with the text of the website
Active comparator: questionnaire
Comparator: usual care
Men aged 50-75 years con-
sidering PSA screening in a
primary care setting (UK):
129 (Web)/ 126 (paper)/127
(questionnaire)/ 132 (usual
care)
RCT, 4 groups: 2 inter-
vention groups (Web-
and paper-based) and 2
control groups (question-
naire and usual care)
Evans 2010 [26]
aRCT: randomized controlled trial.
bPSA: prostate-specific antigen.
cIPDAS: International Patient Decision Aids Standards.
Risk of Bias in Included Studies
Assessments of the risk of bias for each study are summarized
in Multimedia Appendix 3 and the authors’ support for each
judgment are presented in Multimedia Appendix 4. Random
sequence generation was rated as being at low risk of bias in
most of the studies (6/7, 86%) and unclear risk of bias in one
study. Allocation concealment was considered low risk of bias
in five studies (5/7, 71%) and unclear risk in the remaining two
studies.
Blinding of participants and personnel was assessed as being
at low risk of bias in one study (1/7, 14%), unclear risk of bias
in four studies (4/7, 57%), and high risk in two studies (2/7,
29%) [20,21]. All studies were evaluated as being a low risk of
bias regarding blinding of outcome assessment. All studies were
rated as low risk of attrition bias that relates to incomplete
outcome data. Five studies (5/7, 71%) were classified as unclear
risk of bias regarding selective reporting due to the lack of
information about public registration of the trial protocol. The
other two studies had a registered protocol and were rated as
low risk of bias for the selective reporting parameter. When
assessing other sources of bias, six studies were rated as low
risk of bias (6/7, 86%). The remaining study was considered
unclear risk of bias as study groups were not similar in size [20].
Effects of Interventions
The summary of the findings is found in Multimedia Appendix
5.
Knowledge
All seven studies assessed patient knowledge in the
meta-analysis. Studies tested knowledge through questionnaires
based on the content of the decision aids. The number of correct
answers was transformed into a scale ranging from 0% (no
correct answers) to 100% (all correct answers).
Web-Based Decision Aids Versus Usual Care
Four studies included knowledge comparisons for this outcome
in the meta-analysis. One study used a different way for grading
the questionnaire (1 point for a correct answer, 0 for any
unanswered item, and –1 for an incorrect answer), so data could
not be transformed for the scale described above. In addition,
no standard deviations could be obtained; thus data could not
be pooled [26]. Compared to the usual care, patients allocated
to Web-based decision aids had higher average knowledge
scores (SMD 0.46; 95% CI 0.18-0.75; Figure 2). The study that
was not included in the meta-analysis showed a higher
statistically significant average score for the Web-based decision
aid group in comparison with the usual care. Four of the five
RCTs assessing knowledge for Web-based decision aids
compared to usual care demonstrated a statistically significant
improvement in knowledge in the Web-based decision aid group
[19-24]. Taylor et al reassessed knowledge at 13 months, and
the Web-based decision aid group continued to register a
statistically significant increase in median scores compared to
the usual care group [25].
Web-Based Versus Printed Decision Aids
Four studies assessed knowledge for the comparison of
Web-based to printed decision aids, but only data from two
studies could be pooled. The scale used by Evans et al was not
convertible to 0%-100% scale [24]. Additionally, standard
deviations for study results could not be obtained for the Evans
et al and Krist et al studies; these studies did not find any
differences between groups regarding this outcome. No
differences in the average knowledge scores were found for this
comparison (SMD 0.00; 95% CI –0.11 to 0.11; Figure 2)
[21,26].
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Figure 2. Forest plots of standardized mean differences for knowledge. A) Web-based decision aids (DA) versus usual care, B) Web-based decision
aids versus printed decision aids, C) Web-based decision versus video decision aids.
Web-Based Versus Video Aids
With regard to the comparison of Web-based decision to video
decision aids, the Web-based group registered lower average
knowledge scores (SMD –0.50; 95% CI –0.88 to –0.12; Figure
2) for the pooled data for two studies. Frosch et al found a
smaller nonstatistically significant difference between the two
groups when only the participants who reviewed the complete
set of materials were considered for analysis [22].
Decisional Conflict
Six of the seven studies measured patient decisional conflict
using the decisional conflict scale [20-25]. The decisional
conflict scale consists of five subscales, and total scores range
from 0 (no decisional conflict) to 100 (extremely high decisional
conflict). When comparing Web-based aids to usual care or
alternative formats of decision aids, a negative score corresponds
to a reduction in decisional conflicts, which favors Web-based
decision aids.
Web-Based Decision Aids Versus Usual Care
Five studies compared Web-based decision aids to usual care
in terms of decisional conflict [22,23,26]. It was not possible
to pool data from two studies due to lack of standard deviation
of the results [21,26]. Krist et al did not find a significant
difference between the two groups in contrast with the findings
of Evans et al who reported a significant higher decisional
conflict for the usual care group [21,26]. Frosch et al reported
the results using subscales without providing standard deviation
data; this study finding showed significantly higher decisional
conflict for the usual care group in the subscales of “feeling
informed” and “support in decision making”, and no difference
was found for the subscales “uncertainty” and “having made
an effective decision” [22]. The overall MD for decisional
conflict comparing Web-based decision aids versus usual care
was –7.07% (95% CI –9.44 to –4.71; Figure 3).
Web-Based Decision Versus Printed Decision Aids
Four studies assessed decisional conflict by comparing
Web-based decision to printed decision aids [21,24-26]. The
MD for pooled data from two studies was 0.68 (95% CI –1.46
to 2.83; Figure 3). Data from the Evans et al and Krist et al
studies could not be included for meta-analysis because standard
deviations could not be obtained [21,26]. Reported mean scores
for decisional conflicts were similar for the two groups in the
Krist et al study [21]. Evans et al did not find any statistically
significant differences for decisional conflict when a Web-based
decision aid was compared to a printed one [26].
Web-Based Decision Versus Video Decision Aids
Ilic et al did not find any statistical differences regarding mean
decisional conflict scores for patients when exposed to
Web-based decision compared to video decision aids [25].
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Figure 3. Forest plots of mean differences for decisional conflict. A) Web-based decision aids (DA) versus usual care, B) Web-based decision aids
versus printed decision aids.
Participation in Decision Making
Three of the seven studies evaluated participation in decision
making using the Control Preferences Scale (CPS) [21,23,25],
which consists of five statements (A to E), two of which reflect
patient controlled decision making, another one refers to shared
decision making, and the last two reflect practitioner-controlled
decision making. Decision aids are intended to enhance a
patient’s active role in decision making. Therefore, a pooled
RR >1 for group differences in CPS statements A to C favors
Web-based decision aids, and a pooled RR <1 for statements
D and E also favors Web-based decision aids.
Web-Based Decision Aids Versus Usual Care
When comparing Web-based decision aids to usual care in terms
of a patient-controlled or active role in the decision-making
process, the pooled RR was 1.06 (95% CI 0.97-1.16; Figure 4).
For the practitioner-controlled role, a pooled RR of 0.50 was
obtained, which compared Web-based decision aids to usual
care (95% CI 0.31-0.81; Figure 4).
Web-Based Decision Versus Printed Decision Aids
Regarding patients who assumed an active role according to the
CPS, the pooled RR was 0.96 (95% CI 0.77-1.19; Figure 5).
The pooled RR for the same comparison for a collaborative role
in decision making was 1.12 (95% CI 0.78-1.60; Figure 5).
Finally, when pooling data that compared Web-based decision
to printed decision aids in terms of a passive role according to
the CPS, the RR obtained was 0.83 (95% CI 0.47-1.48; Figure
5).
Web-Based Decision Versus Video Decision Aids
Ilic et al was the only study assessing participation in decisions
comparing Web-based decision to video decision aids. No
statistically significant differences between groups were found
for active (RR 0.89; 95% CI 0.66-1.21), collaborative (RR 1.15;
95% CI 0.68-1.95), or passive patient role in decision making
according to the CPS (RR 1.47; 95% CI 0.26-8.46) [25].
Screening Behavior: Preferred Option
Three studies investigated the preferred patient options
concerning prostate screening using the PSA test [20,22,23];
Evans et al and Ilic et al evaluated answers using a 5-point
Likert-like response scale [25,26]. Allen et al reported agreement
with the statement “want to be screened” [23].
Web-Based Decision Aids Versus Usual Care
The pooled RR for two studies comparing the preference for
having a PSA test for patients using a Web-based decision aid
in comparison to usual care was 0.84 (95% CI 0.59-1.21; Figure
6).
Web-Based Decision Versus Printed Decision Aids
When comparing Web-based decision to printed decision aids,
the overall pooled RR indicating a preference for PSA screening
was 0.93 (95% CI 0.61-1.41; Figure 6).
Web-Based Decision Versus Video Decision Aids
Ilic et al assessed the preference for the PSA screening test with
a 5-point response scale. When comparing those who responded
either “definitely want” and “probably want” in the Web-based
decision aid and video groups, there was no significant
difference (RR 1.29; 95% CI 0.99-1.67) [25].
Screening Behavior: PSA Test
Using different methods, five studies investigated the actual
choice of PSA screening: (1) Evans et al asked general
practitioners to review participant’s medical records [26], (2)
Frosch et al also relied on medical records [22], (3) Taylor et
al assessed patients’ self-reported PSA screening at 13 months
[24], (4) Krist et al used patients’ reports of PSA tests ordered
[19], and (5) Frosch et al searched for PSA test requests in
medical records [20].
Web-Based Decision Aids Versus Usual Care
When comparing Web-based decision aids to usual care groups
after pooling data for screening uptake, the obtained RR was
1.0 (95% CI 0.89-1.11; Multimedia Appendix 6).
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Figure 4. Forest plots of relative risks for participation in decision making. A) Patient controlled or shared decision making: Web-based decision aid
(DA) versus usual care, B) Practitioner controlled decision making: Web-based decision aid versus usual care.
Figure 5. Forest plot of relative risks for participation in decision making: Web-based decision aids versus printed decision aids (DA). A) Patient
controlled, B) Shared decision making, C) Practitioner controlled.
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Figure 6. Forest plot of relative risks for screening behavior - preference for prostate-specific antigen test. A) Web-based decision aids (DA) versus
usual care, B) Web-based decision aids versus printed decision aids.
Web-Based Decision Aids Versus Printed Decision Aids
The overall pooled RR was 1.04 (95% CI 0.97-1.12; Multimedia
Appendix 6) when comparing PSA tests in patients exposed to
Web-based decision aids to patients receiving printed decision
aids.
Web-Based Decision Aids Versus Video Decision Aids
The only study assessing PSA test uptake in patients receiving
a Web-based decision aid versus patients receiving a video
decision aid revealed a slight difference for the comparison (RR
1.12; 95% CI 1.0-1.25) [20].
Sensitivity Analysis
We investigated the potential bias resulting from including
studies that were assessed as high risk of bias for any of the
seven criteria considered, which resulted in exclusion of two
studies for this analysis [20,21]. Most results remained similar,
with the following exception: the differences in knowledge
between Web-based decision and video groups became
nonsignificant. The difference for a practitioner-controlled role
in decision making between Web-based decision aids and usual
care also became nonsignificant. After applying a fixed-effect
model, the results were also compared to the results retrieved
in the first analysis with the random-effect model. Results were
similar for all outcomes and comparisons, with one exception.
When comparing Web-based decision aids to usual care for a
patient active or collaborative role in decision, with a slight
decimal change, the difference became significant. These similar
results of fixed-effect model to random-effect model diminish
risk of bias due to “small study effects” (ie, the potential of the
included small studies to overestimate effect sizes).
Taking into account IPDAS criteria [11], decision aids should
offer a values clarification tool. After a verification process,
which included contact with authors, Ilic et al was the only one
of the included studies that did not contain such tool. We
conducted the analysis after removal of this study. The results
were similar to those obtained when the study was included.
When using mean differences instead of standardized mean
differences for knowledge, results were similar for the
comparisons of Web-based decision aids versus usual care (MD
10.66%; CI 95% 6.78-14.53), Web-based decision versus printed
decision aids (MD –0.01%; CI 95% –2.23 to 2.22), and
Web-based decision versus video decision aids (MD –11.9%;
CI 95% –19.19 to –4.61).
Heterogeneity
Statistically significant heterogeneity was found for knowledge
when comparing Web-based decision aids to usual care.
Discussion
Principal Findings and Evidence
In comparison with usual care, Web-based decision aids
significantly increased knowledge, reduced decisional conflict,
and reduced the practitioner-controlled role in the
decision-making process. No differences were found regarding
patients assuming an active or collaborative role in decision
making or in terms of screening behavior. When comparing
Web-based decision with printed decision aids, no differences
were found for knowledge, decisional conflict, participation in
decision, or screening behavior. Compared to video decision
aids, Web-based decision aids showed lower average knowledge
scores and a slight decrease in PSA screening uptake, while no
differences were found regarding participation in decision
making. None of the studies assessed decisional conflict for
these comparisons.
There is high-quality evidence that suggests that Web-based
decision aids when compared to printed decision aids perform
similarly in improving men’s knowledge regarding prostate
cancer screening and reducing decisional conflict. There is
moderate-quality evidence that Web-based decision compared
to printed decision aids show no differences in screening
behavior. There is also low-quality evidence that Web-based
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decision aids resulted in lower knowledge scores when compared
with video decision aids.
Interpretation the Context of Existing Literature
Our results are similar to those from other systematic reviews
and meta-analyses indicating the superiority of decision aids
(in any format) in comparison with usual care, but to our
knowledge, our study is the first to compare Web-based decision
aids to alternative formats in the context of prostate cancer
screening decisions. Stacey et al, in a Cochrane meta-analysis
of decision aids for people facing screening or treatment issues,
found decision aids to improve people’s knowledge, reduce
decisional conflict, promote an active patient role in decision
making, and reduce the number of patients choosing to undergo
PSA screening [13]. In a systematic review and meta-analysis
of features of computer-based decision aids for any
preference-sensitive medical decision, Syrowatka et al indicated
that decision aids are associated with significant knowledge
improvement and decrease in decisional conflict. However,
results were limited by high levels of heterogeneity [15]. Ilic et
al, in a systematic review assessing the effectiveness of decision
aids for decision making in prostate cancer testing, also reported
a reduction in decisional conflict and a statistically significant
improvement in knowledge [14].
Syrowatka et al reported that computer-based decision aids were
associated with significant improvements in knowledge and
decisional conflict compared to usual care or alternative aids
[15]. On the other hand, our results show Web-based decision
aids perform similarly to printed decision aids in terms of
decision quality outcomes. Comparisons should be made with
caution, since the systematic review by Syrowatka et al
addressed all computer-based decision aids (not only
Web-based) and any preference-sensitive medical decision. It
may not be surprising that Web-based and printed decision aids
perform similarly in the context of a trial, since the contents of
the decision aid in both arms is the same. Therefore, the current
evidence supports the use of decision aids. However, either
decision aid format may be used depending on individual
patient’s preference. In addition, we hypothesize that in a busy
day-to-day clinical practice, with limited time to talk to patients,
Web-based decision aids may have greater potential, allowing
patients to easily access and review the material prior to the
encounter with the physician, which may impact the shared
decision-making process.
Only two studies compared Web-based to video decision aids,
which limits our conclusions, particularly concerning the fact
that Web-based decision aids showed lower average knowledge
scores [20,25]. However, we can hypothesize that older men
making a prostate cancer screening decision may not be very
familiar with internet use. Of note, in Frosch et al, the video
decision aid population arm had a specifically allocated time to
watch the video, which was different from the Web-based
decision aid group. This difference may have increased
adherence to video visualization. This study showed that the
video group had significantly more probability of reviewing the
materials, while in the Web-based decision aid group, only
53.5% watched the entire presentation, and 39.5% had not
reviewed any part of it. In fact, the authors reported that for
those in the Web-based decision aid group who reviewed the
entire presentation, knowledge scores were similar to those from
the video group [20]. More studies are needed in order to address
the comparison of decision aids reviewed at an assigned versus
self-allocated time.
Strengths and Limitations
Among the included studies, the risk of bias was higher for the
blinding of participants and personnel criteria. Post-hoc analysis
removing studies at high risk of bias yielded the same results,
except that no differences were found for knowledge comparing
Web-based to video decision aids and no differences for a
practitioner-controlled role in decision making when comparing
Web-based decision aids to usual care.
Several limitations must be considered while analyzing our
conclusions. For most outcomes, the number of studies was
low, making it difficult to assess for publication bias. The
different contents of the decision aids of each study also limited
their comparison. We tried to pool data only when the same
scale or procedure was used to evaluate each outcome. However,
different ways of formulating the questions may also pose a
limitation to our conclusions. The way studies measured
screening behavior could also have introduced bias. The methods
used, such as self-reported screening, review of medical records,
and evaluation of intention to undergo screening, may not be
reliable. PSA screening decisions may have to be made by men
several times in their life, so lack of long-term follow-up in the
included studies also limits the understanding of the impact of
Web-based decision aids over time. Taylor et al was the study
with the longest follow-up (13 months) [24].
Some studies mention visualization rates of the decision aids.
Allen et al refers rates from 23%-59% in the intervention
Web-based decision aid group [23]. In Frosch et al, 86.7% of
the Web-based decision aid arm participants at least clicked on
the link provided [22]. It is possible that if all men effectively
viewed the materials, the impact of decision aids could be
amplified. Results could also have been influenced due to the
fact that people in the printed decision aid arms could have the
decision aid with them while answering the questionnaires.
Finally, participants in the majority of included studies were
white men with high educational levels, which limits the
generalization of results for other populations, such as low
literacy men and cultural minorities. Allen et al addressed a low
literacy population in nonclinical settings (worksites) that
differed from the other included studies [23]. Taylor et al also
included many participants from a low socioeconomic
background [24]. More trials should focus on these populations
and investigate the delivery of decision aids in different settings.
We hypothesize that the statistically significant heterogeneity
found for knowledge when comparing Web-based decision aids
and usual care in conjunction with Web-based to video decision
aids may be due to the fact that the tests used for this assessment
in the included studies were not standardized.
Conclusions
According to this analysis, the Web format seems to have a
similar effect to printed or video decision aids in terms of
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increase in knowledge and decrease in decisional conflict. This
provides evidence to use decision aids to support a patient’s
prostate cancer screening decision, whether it is a Web-based
decision aid or alternative format like a printed or video version.
Of note, most included studies were published 7 or more years
ago. In the last several years, the internet has become even more
ubiquitous and easy to use with many public places providing
it at no cost, which may be an important feature to increase
access to decision aids. Another potential advantage, especially
for health preference sensitive issues, is the anonymity that Web
allows. Increasingly more decision aids will likely become
available through this media, and more men will be skilled
enough to search for them online. More RCTs are needed to
further compare the impact of these alternative decision aid
formats in decision making and to analyze their influence not
only in the short term, but also over time. In addition, more
studies are needed to deepen our understanding of the unique
features of Web-based decision aids, such as virtual connectivity,
interactivity, tailoring, as well as to compare Web-based decision
aids with video and printed decision aids in terms of
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